Literature DB >> 22257841

Good interobserver agreement was attainable on outcome adjudication in patients with stable coronary heart disease.

Erik Kjoller1, Jorgen Hilden, Per Winkel, Niels J Frandsen, Soren Galatius, Gorm Jensen, Jens Kastrup, Jorgen Fischer Hansen, Hans J Kolmos, Christian M Jespersen, Per Hildebrandt, Christian Gluud.   

Abstract

OBJECTIVE: In clinical trials, agreement on outcomes is of utmost importance for valid estimation of intervention effects. As there is limited knowledge about adjudicator agreement in cardiology, we examined the level of agreement among three cardiology specialists adjudicating all possible events in a randomized controlled clinical trial of patients with stable coronary heart disease. STUDY DESIGN AND
SETTING: All information (hospital records, death certificates, etc.) was forwarded to two randomly selected blinded adjudicators. If they disagreed, the third arbiter had to choose the more likely of the two alternatives. Files of 5,475 nonfatal and 362 fatal events were evaluated.
RESULTS: For nonfatal outcomes, pairwise kappa values ranged from 0.75 to 0.80. The three adjudicators had 4.3%, 9.5%, and 6.1% of their nonfatal outcome classifications overruled by their arbiter. If stable angina pectoris, unstable angina pectoris, and acute myocardial infarction were treated as one, agreement increased minimally. For fatal outcomes, the pairwise kappa values ranged from 0.65 to 0.90. The three adjudicators had 12%, 9%, and 10% of their death classifications overruled.
CONCLUSION: Specialists in cardiology can attain a reasonably high agreement on outcomes in patients with stable coronary heart disease. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22257841     DOI: 10.1016/j.jclinepi.2011.09.011

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  7 in total

1.  10-Year Associations Between Tumor Necrosis Factor Receptors 1 and 2 and Cardiovascular Events in Patients With Stable Coronary Heart Disease: A CLARICOR (Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease) Trial Substudy.

Authors:  Axel C Carlsson; Toralph Ruge; Erik Kjøller; Jørgen Hilden; Hans Jørn Kolmos; Ahmad Sajadieh; Jens Kastrup; Gorm Boje Jensen; Anders Larsson; Christoph Nowak; Janus Christian Jakobsen; Per Winkel; Christian Gluud; Johan Ärnlöv
Journal:  J Am Heart Assoc       Date:  2018-04-23       Impact factor: 5.501

2.  Predictors for major cardiovascular outcomes in stable ischaemic heart disease (PREMAC): statistical analysis plan for data originating from the CLARICOR (clarithromycin for patients with stable coronary heart disease) trial.

Authors:  Per Winkel; Janus Christian Jakobsen; Jørgen Hilden; Theis Lange; Gorm Boje Jensen; Erik Kjøller; Ahmad Sajadieh; Jens Kastrup; Hans Jørn Kolmos; Anders Larsson; Johan Ärnlöv; Christian Gluud
Journal:  Diagn Progn Res       Date:  2017-03-29

3.  Rivaroxaban Once-Daily vs. Dose-Adjusted Vitamin K Antagonist on Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF): Rationale and Design of an Investigator-Initiated Multicenter Randomized Prospective Open-Labeled Pilot Clinical Study.

Authors:  Iksung Cho; Jaewon Oh; In-Cheol Kim; Hyemoon Chung; Jung-Hee Lee; Hyue Mee Kim; Young Sup Byun; Byung-Su Yoo; Eui-Young Choi; Wook-Jin Chung; Wook Bum Pyun; Seok-Min Kang
Journal:  Front Cardiovasc Med       Date:  2022-01-12

4.  Prognosis and Reclassification by YKL-40 in Stable Coronary Artery Disease.

Authors:  Jakob Schroder; Janus Christian Jakobsen; Per Winkel; Jørgen Hilden; Gorm Boje Jensen; Ahmad Sajadieh; Anders Larsson; Johan Ärnlöv; Marina Harutyunyan; Julia S Johansen; Erik Kjøller; Christian Gluud; Jens Kastrup
Journal:  J Am Heart Assoc       Date:  2020-03-02       Impact factor: 5.501

5.  Prognostic value of 12 novel cardiological biomarkers in stable coronary artery disease. A 10-year follow-up of the placebo group of the Copenhagen CLARICOR trial.

Authors:  Per Winkel; Janus Christian Jakobsen; Jørgen Hilden; Gorm Boje Jensen; Erik Kjøller; Ahmad Sajadieh; Jens Kastrup; Hans Jørn Kolmos; Kasper Karmark Iversen; Mette Bjerre; Anders Larsson; Johan Ärnlöv; Christian Gluud
Journal:  BMJ Open       Date:  2020-08-20       Impact factor: 2.692

6.  Prognostic value of routinely available data in patients with stable coronary heart disease. A 10-year follow-up of patients sampled at random times during their disease course.

Authors:  Per Winkel; Janus Christian Jakobsen; Jørgen Hilden; Gorm Jensen; Erik Kjøller; Ahmad Sajadieh; Jens Kastrup; Hans Jørn Kolmos; Anders Larsson; Johan Ärnlöv; Christian Gluud
Journal:  Open Heart       Date:  2018-09-05

7.  Pregnancy Associated Plasma Protein-A as a Cardiovascular Risk Marker in Patients with Stable Coronary Heart Disease During 10 Years Follow-Up-A CLARICOR Trial Sub-Study.

Authors:  Erik Nilsson; Jens Kastrup; Ahmad Sajadieh; Gorm Boje Jensen; Erik Kjøller; Hans Jørn Kolmos; Jonas Wuopio; Christoph Nowak; Anders Larsson; Janus Christian Jakobsen; Per Winkel; Christian Gluud; Kasper K Iversen; Johan Ärnlöv; Axel C Carlsson
Journal:  J Clin Med       Date:  2020-01-18       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.